17.74
+0.48(+2.78%)
Currency In USD
| Previous Close | 17.26 |
| Open | 17.31 |
| Day High | 18.06 |
| Day Low | 17.28 |
| 52-Week High | 18.06 |
| 52-Week Low | 8.73 |
| Volume | 17.59M |
| Average Volume | 6.7M |
| Market Cap | 12.11B |
| PE | -16.28 |
| EPS | -1.09 |
| Moving Average 50 Days | 13.96 |
| Moving Average 200 Days | 11.69 |
| Change | 0.48 |
If you invested $1000 in Roivant Sciences Ltd. (ROIV) since IPO date, it would be worth $1,705.77 as of October 21, 2025 at a share price of $17.74. Whereas If you bought $1000 worth of Roivant Sciences Ltd. (ROIV) shares 3 years ago, it would be worth $3,995.5 as of October 21, 2025 at a share price of $17.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle disease,
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
GlobeNewswire Inc.
Sep 11, 2025 8:30 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List. This is Roivant’s first time bein
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire Inc.
Sep 03, 2025 5:01 PM GMT
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 les